JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB106110

Anti-Alpha Dystroglycan antibody [2238]

Be the first to review this product! Submit a review

|

(6 Publications)

Mouse Monoclonal DAG1 antibody. Suitable for WB and reacts with Mouse, Rat, Human samples. Cited in 6 publications. Immunogen corresponding to Native Full Length Protein corresponding to Cow Dystroglycan.

View Alternative Names

Dystroglycan 1, Dystroglycan, Dystrophin-associated glycoprotein 1

1 Images
Western blot - Anti-Alpha Dystroglycan antibody [2238] (AB106110)
  • WB

Lab

Western blot - Anti-Alpha Dystroglycan antibody [2238] (AB106110)

Lanes 1 - 6 : Merged signal (red and green). Green - ab106110 observed at 75-100 kDa. Red - loading control ab181602 (Rabbit Anti-GAPDH antibody [EPR16891]) observed at 37 kDa.

ab106110 was shown to react with DAG1 in Western blot. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with ab106110 and ab181602 (Rabbit Anti-GAPDH antibody [EPR16891]) overnight at 4 °C at a 1 in 100 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.

All lanes:

Western blot - Anti-Alpha Dystroglycan antibody [2238] (ab106110) at 1/100 dilution

Lane 1:

Human brain tissue lysate at 20 µg

Lane 2:

SH-SY5Y cell lysate at 20 µg

Lane 3:

Mouse brain tissue lysate at 20 µg

Lane 4:

Mouse heart tissue lysate at 20 µg

Lane 5:

Rat brain tissue lysate at 20 µg

Lane 6:

Rat heart tissue lysate at 20 µg

Predicted band size: 97 kDa

Observed band size: 75-100 kDa

false

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

2238

Isotype

IgG2b

Carrier free

No

Reacts with

Mouse, Rat, Human

Applications

WB

applications

Immunogen

Native Full Length Protein corresponding to Cow Dystroglycan.

O18738

Epitope

Glycoepitope on brain bovine alpha-dystroglycan

Specificity

<strong>ab106110 is specific for a glycoepitope present on brain Alpha Dystroglycan. The clone was generated using enriched bovine brain Alpha dystroglycan, and has been shown to bind Alpha Dystroglycan from enriched mouse, rat, rabbit and bovine brain tissues but did not bind Alpha Dystroglycan from striated muscle, peripheral nerve or kidney (PMID: 16709410&#41;.</strong>

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/100", "WB-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/100", "WB-species-notes": "<p></p>" }, "Rat": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/100", "WB-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein G
Purification notes
0.2 μm filtered antibody solution
Storage buffer
Preservative: 0.02% Sodium azide Constituents: PBS, 0.1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Alpha dystroglycan (alpha-DG) a subunit of the dystroglycan complex acts mechanically as an important cell surface receptor. This protein binds extracellular matrix components like laminin agrin and perlecan facilitating cell-matrix interactions. Alpha-DG has a molecular weight of approximately 156 kDa and comes from post-translational modification of a precursor protein. Researchers frequently use the terms "alpha" and "DG" when referencing this target. This protein shows wide expression across various tissues including skeletal cardiac and smooth muscle as well as in the brain and peripheral nerves.
Biological function summary

Alpha-DG performs roles critical for stabilizing tissue architecture by connecting the actin cytoskeleton to the extracellular matrix. As a part of the dystroglycan complex alpha-DG associates with beta-dystroglycan contributing to the linkage between dystrophin and the extracellular components. It ensures structural integrity and signal transduction that are necessary for tissue maintenance and function. Disrupted interactions can lead to compromised tissue stability which reflects its importance in cellular contexts.

Pathways

Alpha-DG integrates into the dystrophin-glycoprotein complex (DGC) a significant component within the mechanotransduction and cellular signaling pathways. The complex notably participates in the PI3K/AKT signaling pathway important for survival and metabolism along with interactions involving integrins. Through its role in these pathways alpha-DG engages with proteins like dystrophin and sarcoglycans facilitating proper signaling and structural support which is important for normal muscle function.

Alpha-DG connects closely with dystroglycanopathies which involve a group of muscular dystrophies like congenital muscular dystrophy. These conditions result from improper glycosylation of α-DG affecting its binding ability and compromising muscular integrity. Alpha-DG also relates to conditions such as cancer where altered glycosylation patterns may impact tumor progression and cell invasion. In these contexts alpha-DG interacts with beta-dystroglycan indicating that both defects in glycosylation and associated proteins contribute to disease mechanisms.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

The dystroglycan complex is involved in a number of signaling events and processes including laminin deposition and extracellular matrix assembly, acetylcholine receptor clustering, sarcolemmal stability, cell survival, peripheral nerve myelination, nodal structure, cell migration, epithelial polarization, and epithelium branching morphogenesis (By similarity). Required for the formation of photoreceptor ribbon synapses, and long-term maintenance of inhibitory synapses in cerebellar Purkinje cells (By similarity). Also involved in the positive regulation of cartilage formation through agrin (AGRN) binding and up-regulation of SOX9, a transcription factor that plays a key role in chondrocytes differentiation (PubMed : 26290588).. Alpha-dystroglycan. Extracellular peripheral glycoprotein that acts as a receptor for extracellular matrix proteins containing laminin-G domains. As a receptor for laminin is involved in extracellular matrix assembly, and activation of the PI3K/AKT pathway regulating cell apoptotic signals in muscle (By similarity). Binding of laminin LAMA1 to alpha-dystroglycan also initiates a signaling cascade in which Src kinases, c-Src or c-Fyn, phosphorylate syntrophin modifying its interaction with the adapter protein GRB2; this triggers recruitment of guanyl-nucleotide exchange factor SOS1 and activation of RAC1, finally resulting in c-Jun phosphorylation by MAPK8/JNK1 (By similarity). As a receptor for laminin LAMA1 is also involved in epithelium branching morphogenesis in salivary glang and lung (By similarity). Receptor for laminin-2 (LAMA2) and agrin in peripheral nerve Schwann cells (By similarity). Also acts as a receptor for laminin LAMA5 (By similarity). In muscle cells, it is a receptor for laminin-1 (also known as laminin-111 or EHS laminin) and is involved in the stimulation of agrin-induced acetylcholine receptor (AChR) clustering, and formation of the synaptic basement membrane. It is required for acetylcholinesterase (AChE) localization at the neuromuscular junctions (NMJ) through its binding with perlecan (HSPG2) and is, therefore, involved in the down-regulation of colinergic synaptic transmission (By similarity). In the retina, it is required for the formation of photoreceptor ribbon synapses through its interaction with pikachurin (EGFLAM) (By similarity). Involved in the positive regulation of cartilage formation through agrin (AGRN) binding and up-regulation of SOX9, a transcription factor that plays a key role in chondrocytes differentiation (PubMed : 26290588).. Beta-dystroglycan. Transmembrane protein that plays important roles in connecting the extracellular matrix to the cytoskeleton. Acts as a cell adhesion receptor in both muscle and non-muscle tissues. Receptor for both DMD and UTRN and, through these interactions, scaffolds axin to the cytoskeleton. Also functions in cell adhesion-mediated signaling and implicated in cell polarity.. Alpha-dystroglycan. (Microbial infection) Acts as a receptor for lassa virus and lymphocytic choriomeningitis virus glycoprotein and class C new-world arenaviruses (PubMed : 16254364, PubMed : 17360738, PubMed : 19324387). Acts as a Schwann cell receptor for Mycobacterium leprae, the causative organism of leprosy, but only in the presence of the G-domain of LAMA2 (PubMed : 9851927).
See full target information DAG1

Publications (6)

Recent publications for all applications. Explore the full list and refine your search

Cell death & disease 15:201 PubMed38461287

2024

Deficiency of skeletal muscle Agrin contributes to the pathogenesis of age-related sarcopenia in mice.

Applications

Unspecified application

Species

Unspecified reactive species

Jie Chen,Hong Chen,Xia Dong,Tiankun Hui,Min Yan,Dongyan Ren,Suqi Zou,Shunqi Wang,Erkang Fei,Wenhua Zhang,Xinsheng Lai

Acta neuropathologica 138:1033-1052 PubMed31463571

2019

The dystroglycan receptor maintains glioma stem cells in the vascular niche.

Applications

Unspecified application

Species

Unspecified reactive species

Bryan W Day,Justin D Lathia,Zara C Bruce,Rochelle C J D'Souza,Ulrich Baumgartner,Kathleen S Ensbey,Yi Chieh Lim,Brett W Stringer,Seçkin Akgül,Carolin Offenhäuser,Yuchen Li,Paul R Jamieson,Fiona M Smith,Courtney L R Jurd,Thomas Robertson,Po-Ling Inglis,Zarnie Lwin,Rosalind L Jeffree,Terrance G Johns,Krishna P L Bhat,Jeremy N Rich,Kevin P Campbell,Andrew W Boyd

American journal of translational research 10:3053-3067 PubMed30416650

2018

Inducible pluripotent stem cell-derived mesenchymal stem cell therapy effectively protected kidney from acute ischemia-reperfusion injury.

Applications

Unspecified application

Species

Unspecified reactive species

Sheung-Fat Ko,Yen-Ta Chen,Christopher Glenn Wallace,Kuan-Hung Chen,Pei-Hsun Sung,Ben-Chung Cheng,Tien-Hung Huang,Yi-Ling Chen,Yi-Chen Li,Hsueh-Wen Chang,Mel S Lee,Chih-Chao Yang,Hon-Kan Yip

The Journal of neuroscience : the official journal of the Society for Neuroscience 34:13892-905 PubMed25319686

2014

LRP4 is critical for neuromuscular junction maintenance.

Applications

WB

Species

Mouse

Arnab Barik,Yisheng Lu,Anupama Sathyamurthy,Andrew Bowman,Chengyong Shen,Lei Li,Wen-cheng Xiong,Lin Mei

Journal of neuropathology and experimental neurology 73:425-41 PubMed24709677

2014

Clinical, pathologic, and mutational spectrum of dystroglycanopathy caused by LARGE mutations.

Applications

Unspecified application

Species

Unspecified reactive species

Katherine G Meilleur,Kristen Zukosky,Livija Medne,Pierre Fequiere,Nina Powell-Hamilton,Thomas L Winder,Abdulaziz Alsaman,Ayman W El-Hattab,Jahannaz Dastgir,Ying Hu,Sandra Donkervoort,Jeffrey A Golden,Ralph Eagle,Richard Finkel,Mena Scavina,Ian C Hood,Lucy B Rorke-Adams,Carsten G Bönnemann

Human molecular genetics 23:618-36 PubMed24087791

2013

Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy.

Applications

Unspecified application

Species

Unspecified reactive species

Colleen E D'Arcy,Sandra J Feeney,Catriona A McLean,Stefan M Gehrig,Gordon S Lynch,Jaclyn E Smith,Belinda S Cowling,Christina A Mitchell,Meagan J McGrath
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com